CFD 属于复杂的高风险金融工具，其杠杆作用可能导致投资者迅速亏损。 84% 的散户投资者因进行 CFD 交易遭受资金损失。 请您谨慎考虑自己是否了解 CFD 操作，以及是否能够接受高额亏损的风险。
Capital Com Australia Pty Ltd Australia (受监管于 ASIC) Capital Com UK Limited 受监管于 Financial Conduct Authority (FCA) Capital Com SV Investments Limited Cyprus / EU (受监管于 CYSEC) Сlosed Joint Stock Company «FinTech Solutions» (受监管于 NBRB) Smart Forex Broker LLC Capital Com Stock and CFD Investing Ltd Seychelles (受监管于 FSA) Capital Com Online Investments Ltd (受监管于 SCB) Our Global Offices

Scan to Download iOS&Android APP

English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文
您也可以联系我们： 致电 +44 20 8089 7893 support@capital.com

交易 NGM Biopharmaceuticals, Inc. - NGM CFD

12.80
0.47%
  • 概括
  • 历史数据
  • 活动
  • 收入报表
  • 资产负债表
  • 现金流
  • 所有权
交易条件
价差 0.06
多头隔夜费

Long position overnight fee

Margin. Your investment $1,000.00
隔夜费用 -0.030779 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
前往平台
-0.030779%
空头隔夜费

Short position overnight fee

Margin. Your investment $1,000.00
隔夜费用 -0.013666 %
Charges from borrowed part ($-0.55)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
前往平台
-0.013666%
隔夜费时间 22:00 (UTC)
最小交易量 1
货币 USD
保证金 20%
上市交易所 United States of America
交易费 0%

*Information provided by Capital.com

关键数据
前收盘价* 12.88
开盘价* 12.68
1 年变化* -1.32%
日范围* 12.39 - 12.86
52 周范围 2.92-18.25
平均交易量（10 天） 342.53K
平均交易量（3 个月) 8.26M
市值 439.69M
市盈率 -100.00K
流通股 81.73M
收入 58.11M
EPS -1.94
股息（收益率 %） N/A
贝塔 1.22
下一个财报发布日期 Feb 27, 2023

所有数据都是由Refinitiv提供的， 除了标有星号的数据， 这是*由 Capital.com 提供的数据

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date 平倉 Change Change (%) 開倉 High Low
Jun 29, 2022 12.80 0.07 0.55% 12.73 12.91 12.32
Jun 28, 2022 12.88 -1.09 -7.80% 13.97 14.24 12.50
Jun 27, 2022 14.68 0.38 2.66% 14.30 14.85 14.13
Jun 24, 2022 14.64 1.16 8.61% 13.48 14.73 13.48
Jun 23, 2022 14.06 0.53 3.92% 13.53 14.06 13.52
Jun 22, 2022 13.75 0.28 2.08% 13.47 14.18 13.47
Jun 21, 2022 13.78 0.25 1.85% 13.53 14.19 13.53
Jun 17, 2022 13.58 0.69 5.35% 12.89 13.95 12.87
Jun 16, 2022 12.86 0.30 2.39% 12.56 13.07 12.34
Jun 15, 2022 12.97 0.46 3.68% 12.51 13.10 12.34
Jun 14, 2022 12.51 0.01 0.08% 12.50 12.66 12.17
Jun 13, 2022 12.31 0.02 0.16% 12.29 12.92 12.08
Jun 10, 2022 12.85 0.31 2.47% 12.54 12.98 12.35
Jun 9, 2022 12.82 -0.48 -3.61% 13.30 13.78 12.43
Jun 8, 2022 13.74 -0.14 -1.01% 13.88 14.80 13.47
Jun 7, 2022 14.03 0.15 1.08% 13.88 14.86 13.63
Jun 6, 2022 13.78 -0.55 -3.84% 14.33 14.66 13.55
Jun 3, 2022 14.49 0.91 6.70% 13.58 14.78 13.45
Jun 2, 2022 13.57 0.77 6.02% 12.80 13.59 12.50
Jun 1, 2022 12.99 -0.90 -6.48% 13.89 14.06 12.99

NGM Biopharmaceuticals, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • 年度
  • 每季度
2016 2017 2018 2019 2020 2021
总收入 85.589 77.141 108.665 103.544 87.368 77.882
收入 85.589 77.141 108.665 103.544 87.368 77.882
总营业费用 93.95 94.566 112.979 152.884 191.201 198.577
销售/一般/行政费用，总计 11.845 14.83 17.265 23.631 27.229 36.865
研究与开发 82.105 79.736 95.714 129.253 163.972 161.712
营业收入 -8.361 -17.425 -4.314 -49.34 -103.833 -120.695
利息收入（费用），非经营净值 1.806 2.358 3.622 6.692 1.939 0.42
其他，净值 0.133 -0.152 0.199 -0.147 -0.593 -0.06
税前净收入 -6.422 -15.219 -0.493 -42.795 -102.487 -120.335
税后净收入 -6.922 -14.159 -0.493 -42.795 -102.487 -120.335
未计算非常项目前的净收益 -6.922 -14.159 -0.493 -42.795 -102.487 -120.335
净收入 -6.922 -14.159 -0.493 -42.795 -102.487 -120.335
普通股股东可获收益 (不含非经常性项目) -6.922 -14.159 -0.493 -42.795 -102.487 -120.335
普通股股东可获收益 (含非經常性項目) -6.922 -14.159 -0.493 -42.795 -102.487 -120.335
摊薄净收入 -6.922 -14.159 -0.493 -42.795 -102.487 -120.335
摊薄后加权平均股 64.9937 64.9937 64.9937 50.2975 68.4754 77.0854
扣除特别项目的每股摊薄盈利 -0.1065 -0.21785 -0.00759 -0.85084 -1.4967 -1.56106
Dividends per Share - Common Stock Primary Issue 0 0 0 0
每股正常摊薄盈利 -0.1065 -0.21785 -0.00759 -0.85084 -1.4967 -1.56106
非常规项目总计 0 0
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
总收入 21.575 16.773 18.575 20.959 20.948
收入 21.575 16.773 18.575 20.959 20.948
总营业费用 49.42 53.393 47.581 48.183 53.529
销售/一般/行政费用，总计 8.721 9.823 8.867 9.454 10.723
研究与开发 40.699 43.57 38.714 38.729 42.806
营业收入 -27.845 -36.62 -29.006 -27.224 -32.581
利息收入（费用），非经营净值 0.114 0.115 0.106 0.085 0.176
其他，净值 0.187 -0.187 0.035 -0.095 -0.045
税前净收入 -27.544 -36.692 -28.865 -27.234 -32.45
税后净收入 -27.544 -36.692 -28.865 -27.234 -32.45
未计算非常项目前的净收益 -27.544 -36.692 -28.865 -27.234 -32.45
净收入 -27.544 -36.692 -28.865 -27.234 -32.45
普通股股东可获收益 (不含非经常性项目) -27.544 -36.692 -28.865 -27.234 -32.45
普通股股东可获收益 (含非經常性項目) -27.544 -36.692 -28.865 -27.234 -32.45
摊薄净收入 -27.544 -36.692 -28.865 -27.234 -32.45
摊薄后加权平均股 76.0341 77.0964 77.4089 77.7871 78.023
扣除特别项目的每股摊薄盈利 -0.36226 -0.47592 -0.37289 -0.35011 -0.4159
Dividends per Share - Common Stock Primary Issue 0 0 0 0
每股正常摊薄盈利 -0.36226 -0.47592 -0.37289 -0.35011 -0.4159
  • 年度
  • 每季度
2016 2017 2018 2019 2020 2021
流动资产总额 234.681 175.533 214.557 355.248 308.426 379.28
现金和短期投资 230.192 173.685 206.633 344.511 295.156 366.253
现金等价物 45.463 25.593 56.923 245.598 147.017 151.795
短期投资 184.729 148.092 149.71 98.913 148.139 214.458
应收账款总额，净额 2.769 0 3.669 5.206 6.433 4.945
Prepaid Expenses 1.72 1.848 4.255 5.531 6.837 8.082
Total Assets 276.994 248.941 246.085 380.403 329.043 402.387
Property/Plant/Equipment, Total - Net 27.194 24.873 23.893 19.475 14.526 14.116
Property/Plant/Equipment, Total - Gross 36.046 40.053 46.093 49.231 50.837 53.084
Accumulated Depreciation, Total -8.852 -15.18 -22.2 -29.756 -36.311 -38.968
Long Term Investments 12.709 45.15 0
Other Long Term Assets, Total 2.41 3.385 7.635 5.68 6.091 8.991
Total Current Liabilities 37.693 36.893 41.486 39.718 42.583 61.355
Accounts Payable 8.424 1.892 5.775 9.026 9.663 5.246
Accrued Expenses 8.934 11.686 14.003 22.991 29.945 38.335
Notes Payable/Short Term Debt 0 0 0 0 0 0
Other Current Liabilities, Total 20.335 23.315 21.708 7.701 2.975 17.774
Total Liabilities 97.182 75.045 59.406 49.684 49 66.74
Total Long Term Debt 0 0 0 0 0 0
Other Liabilities, Total 59.489 38.152 17.92 9.966 6.417 5.385
Total Equity 179.812 173.896 186.679 330.719 280.043 335.647
Preferred Stock - Non Redeemable, Net 294.874 294.874 294.874 0 0
Common Stock 0.011 0.012 0.007 0.067 0.071 0.078
Additional Paid-In Capital 17.57 26.141 39.258 526.771 578.599 754.664
Retained Earnings (Accumulated Deficit) -132.541 -146.7 -147.193 -196.144 -298.631 -418.966
Other Equity, Total -0.102 -0.431 -0.267 0.025 0.004 -0.129
Total Liabilities & Shareholders’ Equity 276.994 248.941 246.085 380.403 329.043 402.387
Total Common Shares Outstanding 64.9937 64.9937 64.9937 66.9603 70.5854 77.9627
Total Preferred Shares Outstanding 0 0
Accounts Receivable - Trade, Net 0
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
流动资产总额 425.849 403.129 395.883 379.28 337.622
现金和短期投资 412.656 390.55 383.429 366.253 329.832
现金等价物 148.113 99.403 145.826 151.795 109.872
短期投资 264.543 291.147 237.603 214.458 219.96
应收账款总额，净额 4.925 3.586 4.4 4.945 0.103
Prepaid Expenses 8.268 8.993 8.054 8.082 7.687
Total Assets 445.541 423.011 415.858 402.387 359.773
Property/Plant/Equipment, Total - Net 13.733 12.79 11.452 14.116 13.006
Property/Plant/Equipment, Total - Gross 51.257 50.027 50.195 53.084 53.329
Accumulated Depreciation, Total -37.524 -37.237 -38.743 -38.968 -40.323
Other Long Term Assets, Total 5.959 7.092 8.523 8.991 9.145
Total Current Liabilities 40.309 45.043 57.728 61.355 44.563
Accounts Payable 7.535 5.141 7.632 5.246 4.815
Accrued Expenses 29.763 31.891 34.72 38.335 34.631
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 3.011 8.011 15.376 17.774 5.117
Total Liabilities 45.964 49.936 61.819 66.74 48.636
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 5.655 4.893 4.091 5.385 4.073
Total Equity 399.577 373.075 354.039 335.647 311.137
Preferred Stock - Non Redeemable, Net 0 0 0 0 0
Common Stock 0.077 0.077 0.078 0.078 0.078
Additional Paid-In Capital 725.693 735.86 745.704 754.664 763.152
Retained Earnings (Accumulated Deficit) -326.175 -362.867 -391.732 -418.966 -451.416
Other Equity, Total -0.018 0.005 -0.011 -0.129 -0.677
Total Liabilities & Shareholders’ Equity 445.541 423.011 415.858 402.387 359.773
Total Common Shares Outstanding 76.9136 77.3072 77.6426 77.9627 78.087
Total Preferred Shares Outstanding 0
  • 年度
  • 每季度
2016 2017 2018 2019 2020 2021
净收入/起跑线 -6.922 -14.159 -0.493 -42.795 -102.487 -120.335
经营活动产生的现金 1.269 -17.413 -7.597 -41.174 -83.496 -73.229
经营活动产生的现金 3.534 6.441 7.223 7.605 6.555 6.089
非现金物品 7.169 8.043 9.254 11.956 16.136 36.809
营运资金的变化 -2.512 -17.738 -23.581 -17.94 -3.7 4.208
投资活动产生的现金 -64.707 -2.796 38.729 48.723 -50.998 -71.65
资本支出 -24.804 -6.422 -5.844 -3.489 -1.879 -1.684
其他投资现金流量项目，总计 -39.903 3.626 44.573 52.212 -49.119 -69.966
融资活动产生的现金 0.231 0.339 0.198 180.751 35.538 149.657
股票的发行（报废），净额 0.231 0.339 2.398 180.751 36.151 149.657
现金净变化 -63.207 -19.87 31.33 188.3 -98.956 4.778
融资现金流项目 -2.2 -0.613 0
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -27.544 -64.236 -93.101 -120.335 -32.45
Cash From Operating Activities -22.225 -45.535 -54.894 -73.229 -35.738
Cash From Operating Activities 1.554 3.118 4.61 6.089 1.427
Non-Cash Items 6.837 19.465 26.838 36.809 9.273
Changes in Working Capital -3.072 -3.882 6.759 4.208 -13.988
Cash From Investing Activities -117.156 -145.88 -93.576 -71.65 -6.853
Capital Expenditures -0.16 -1.355 -1.551 -1.684 -0.285
Other Investing Cash Flow Items, Total -116.996 -144.525 -92.025 -69.966 -6.568
Cash From Financing Activities 140.477 143.801 147.279 149.657 0.668
Issuance (Retirement) of Stock, Net 140.477 143.801 147.279 149.657 0.668
Net Change in Cash 1.096 -47.614 -1.191 4.778 -41.923
Financing Cash Flow Items 0 0 0
投资者名称 投资者类型 流通股百分比 持有股份 股份变动 持有日期 换手率
The Column Group LP Venture Capital 26.5053 21661782 546759 2023-01-31 LOW
Merck Sharp & Dohme Corporation Corporation 15.8517 12955016 0 2022-03-10
EcoR1 Capital, LLC Hedge Fund 7.8745 6435518 5894410 2022-10-18 MED
Fidelity Management & Research Company LLC Investment Advisor 5.1229 4186777 2126738 2022-09-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.7647 3894038 496089 2022-09-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 3.7429 3058965 71412 2022-09-30 LOW
Rieflin (William J L) Individual Investor 3.3947 2774340 1805 2022-03-10 LOW
Avidity Partners Management LP Hedge Fund 2.2002 1798100 1798100 2022-09-30 MED
StepStone Group LP Private Equity 1.9252 1573357 0 2022-09-30 LOW
Chen (Jin-Long) Individual Investor 1.3874 1133893 0 2023-01-17 LOW
First Light Asset Management, LLC Investment Advisor/Hedge Fund 1.1692 955505 -180379 2022-09-30 LOW
Rubric Capital Management LP Hedge Fund 1.0733 877161 79573 2022-09-30 MED
State Street Global Advisors (US) Investment Advisor/Hedge Fund 1.0469 855575 85133 2022-09-30 LOW
Logos Global Management LLC Investment Advisor 1.0401 850000 850000 2022-09-30 HIGH
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.964 787808 141090 2022-09-30 LOW
Euclidean Capital, L.L.C. Investment Advisor 0.9136 746674 0 2022-09-30 LOW
Nuveen LLC Pension Fund 0.904 738810 203372 2022-09-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.9022 737316 8702 2022-09-30 LOW
BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 0.8253 674468 83987 2022-09-30 LOW
Two Sigma Investments, LP Hedge Fund 0.6689 546640 180720 2022-09-30 HIGH

为什么选择 Capital.com？让我们的数字来说话。

Capital.com Group
+500000+

交易者

93000+

每月活跃客户

$57000000+

每月投资额

$31000000+

每月提取金额

交易計算器

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

貿易佣金
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
杠杆
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
投資
交易規模（槓桿 x 投資）：
開倉

平倉

做空 做多
過去的表現並不是未來結果的可靠指標
盈利/失利

NGM Biopharmaceuticals, Inc. Company profile

关于 NGM Biopharmaceuticals Inc.

NGM Biopharmaceuticals, Inc.是一家生物制药公司。 公司专注于发现和开发基于对肝脏和代谢疾病、视网膜疾病和癌症的关键生物途径的科学理解的新型治疗方法。 公司的候选产品包括Aldafermin, MK-3655, NGM621, NGM120, NGM707和NGM438。 Aldafermin是人类激素FGF19的一个工程变体，公司正在开发治疗非酒精性脂肪性肝炎（NASH）的药物。 MK-3655是一种与成纤维细胞生长因子受体1c-beta-klotho，或FGFR1c/KLB结合的激动性抗体，有可能成为治疗NASH的胰岛素增敏剂。 该公司还在开发NGM831，这是一种新型的拮抗剂抗体，旨在阻断纤维蛋白的ILT3的相互作用，以及与其他配体的关系。

Industry: Bio Therapeutic Drugs

333 Oyster Point Blvd
SOUTH SAN FRANCISCO
CALIFORNIA 94080-1978
US

收入报表

  • Annual
  • Quarterly

人们也观看

XRP/USD

0.40 Price
-0.010% 1D Chg, %
多头隔夜费 -0.0500%
空头隔夜费 0.0140%
隔夜费时间 22:00 (UTC)
价差 0.00331

BTC/USD

23,119.80 Price
-0.350% 1D Chg, %
多头隔夜费 -0.0500%
空头隔夜费 0.0140%
隔夜费时间 22:00 (UTC)
价差 60.00

Oil - Crude

78.04 Price
+0.240% 1D Chg, %
多头隔夜费 -0.0218%
空头隔夜费 0.0068%
隔夜费时间 22:00 (UTC)
价差 0.03

US100

12,682.50 Price
-0.100% 1D Chg, %
多头隔夜费 -0.0186%
空头隔夜费 0.0075%
隔夜费时间 22:00 (UTC)
价差 1.8

还在找一位您可以信任的经纪商吗？

加入成为全球500,000万多名交易者的一份子，选择利用Capital.com进行交易吧。

1. 创建和验证您的账户 2. 进行存款 3. 找到适合您的交易